In the past six months, the MIT artificial intelligence spinout Iterative Scopes raised $30 million in funding and secured European approval for its software to help spot the signs of colorectal cancer. Now it’s leap-frogged up to a $150 million round to help bring its computer vision programs to U.S. clinicians.

Artificial pancreas systems have shown in studies that they can be useful in managing diabetes among adults and adolescents, but the youngest children can be especially vulnerable to big swings in blood sugar levels.

Existing meds haven’t delivered on treating the depression that impacts millions of Americans. That’s how Sage Therapeutics sees it, and with partner Biogen, the biopharma thinks it can “raise the bar” for patients and healthcare providers.

To repeat the success of CAR-T therapies in blood cancers, a key direction for solid tumor research focuses on enabling the engineered immune cells to better target those tumors. Now, a group of scientists in Italy has proposed a method to do just that.

Investors and patients will hear more about the future of Sensorion’s failed sudden hearing loss drug in March, once the French biotech gets a clearer picture of a midstage study that didn’t pass muster.

Artificial-intelligence-powered drug designer Schrödinger has absorbed a small company specializing in X-ray crystallography to help boost its ability to map out the shapes of target proteins and find the therapeutic molecules that may best work against them.

Messenger RNA (mRNA) technology became a household name so quickly thanks to the COVID-19 vaccines by Pfizer-BioNTech and Moderna, and, now, biotech leaders are taking a moment to reflect on where the field goes from here.

Eisai made history last year as Biogen’s partner on Aduhelm, the first approved Alzheimer’s treatment in decades. And yes, they know the launch could have gone better.

There are no approved treatments for the process of metastasis, in which cancerous tumors spread to additional sites in the body. Now, researchers say repurposing an FDA-approved med for irregular heartbeat might help.

Amid its continued struggles with the far-ranging recall of many of its CPAP and BiPAP machines and other respiratory devices, one area playing a significant role in keeping Philips’ head above water is its image-guided therapy segment.